

Registry-based observational study of patients with rheumatoid arthritis treated with baricitinib or tofacitinib in a tertiary hospital

Elena Guillén Benítez¹, Mònica Sabaté², Elena Ballarín³, Esther Espartal³, María López³, Montserrat Bosch⁴, Núria Boixareu³, Eduard Diogène³, and Immaculada Danés⁴

¹Vall d'Hebron Hospital Universitari

²Fundació Institut Català de Farmacologia

³Vall d'Hebron University Hospital

⁴Hospital Universitari Vall d'Hebron

July 14, 2023

Abstract

The aim of the study was to describe the use of two Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA) recorded at Vall d'Hebron University Hospital (VHUH) between September 2017-November 2019. The data was extracted from the register of Patients and Treatments and medical records. Out of the thirty-nine patients included 90.0% were women, median age 56 years (IQR 29-72) and disease duration 15 years (IQR 8-20). Tofacitinib was the most used (28 patients). All patients had been previously treated with conventional synthetic disease modifying antirheumatic drugs (csDMARDs), and 79.5% with at least one biological DMARD (bDMARD). In 16 patients (41.0%) disease activity category improved. Treatment was withdrawn in 9 patients, mainly due to lack of efficacy (5). Five patients treated with tofacitinib reported gastrointestinal and/or skin disorders. This study shows the usefulness of registries of treated patients to study the use of the new and expensive drugs.

Hosted file

BJCP-Guillen_etal (2).docx available at <https://authorea.com/users/639525/articles/654799-registry-based-observational-study-of-patients-with-rheumatoid-arthritis-treated-with-baricitinib-or-tofacitinib-in-a-tertiary-hospital>

Hosted file

Figures-Guillen etal .docx available at <https://authorea.com/users/639525/articles/654799-registry-based-observational-study-of-patients-with-rheumatoid-arthritis-treated-with-baricitinib-or-tofacitinib-in-a-tertiary-hospital>